---
title: "BioNTech SE (BNTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BNTX.US.md"
symbol: "BNTX.US"
name: "BioNTech SE"
industry: "Biotechnology"
datetime: "2026-05-19T22:47:51.893Z"
locales:
  - [en](https://longbridge.com/en/quote/BNTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BNTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BNTX.US.md)
---

# BioNTech SE (BNTX.US)

## Company Overview

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.biontech.de](https://www.biontech.de) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 70 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 10.80% |  |
| Net Profit YoY | -77.33% |  |
| P/B Ratio | 1.05 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 22468766589.85 |  |
| Revenue | 3276738215.63 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6.66% | D |
| Profit Margin | -44.64% | E |
| Gross Margin | 39.54% | B |
| Revenue YoY | 10.80% | B |
| Net Profit YoY | -77.33% | E |
| Total Assets YoY | 5.33% | C |
| Net Assets YoY | 4.59% | C |
| Cash Flow Margin | -65.14% | E |
| OCF YoY | 10.80% | B |
| Turnover | 0.13 | E |
| Gearing Ratio | 11.28% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BioNTech SE",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "10.80%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-77.33%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.05",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "22468766589.85",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3276738215.63",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6.66%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-44.64%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "39.54%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "10.80%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-77.33%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.33%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.59%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-65.14%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "10.80%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "11.28%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15.36 | 487/386 | - | - | - |
| PB | 1.05 | 98/386 | 1.26 | 1.16 | 1.07 |
| PS (TTM) | 6.86 | 138/386 | 8.50 | 7.75 | 6.85 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 71% |
| Overweight | 1 | 6% |
| Hold | 4 | 24% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 87.79 |
| Highest Target | 173.93 |
| Lowest Target | 75.47 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BNTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BNTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BNTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BNTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**